Delta Pharm sponsoring methotrexate/misoprostol medical abortion Phase III trial in 1,500 women.
DELTA PHARM WILL CONDUCT METHOTREXATE/MISOPROSTOL MEDICAL ABORTION STUDY in 1,500 women as an alternative to surgical abortion, the private New York City women's reproductive health products company announced Aug. 30. The Phase III study, which has not yet begun enrollment but does have an IND from FDA, will be conducted at 10-12 institutions nationwide that undertake a sufficient volume of surgical abortions to meet the patient population criterion. Delta hopes to file an NDA for the two-drug regimen for medical abortion in 1996.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth